Jochen Utikal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/151075/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical determinants of long-term survival in metastatic uveal melanoma. Cancer Immunology, Immunotherapy, 2022, 71, 1467-1477.	4.2	10
2	TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. European Journal of Cancer, 2022, 161, 99-107.	2.8	10
3	S1â€guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). JDDG - Journal of the German Society of Dermatology, 2022, 20, 235-243.	0.8	8
4	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. Cancers, 2022, 14, 518.	3.7	6
5	ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6. Cancers, 2022, 14, 1071.	3.7	11
6	STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. , 2022, 10, e004384.		21
7	Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers, 2022, 14, 1804.	3.7	4
8	MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – An evaluation of the multicenter prospective skin cancer registry ADOREG. European Journal of Cancer, 2022, 167, 32-41.	2.8	9
9	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Journal of Clinical Oncology, 2022, 40, 3741-3749.	1.6	33
10	Melanoma Cellular Plasticity. International Journal of Molecular Sciences, 2022, 23, 6401.	4.1	0
11	Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. , 2022, 10, e004509.		8
12	Patient preferences for treatment of advanced melanoma: impact of comorbidities. JDDG - Journal of the German Society of Dermatology, 2021, 19, 58-70.	0.8	7
13	IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cellular Immunology, 2021, 359, 104254.	3.0	141
14	ld1 and ld3 Are Regulated Through Matrixâ€Assisted Autocrine BMP Signaling and Represent Therapeutic Targets in Melanoma. Advanced Therapeutics, 2021, 4, 2000065.	3.2	1
15	Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. Cellular Immunology, 2021, 360, 104274.	3.0	8
16	New Biomarkers in Cancers. Cancers, 2021, 13, 708.	3.7	7
17	Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression. Cancers, 2021, 13, 726.	3.7	20
18	Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. Journal of Medical Internet Research, 2021, 23, e23436.	4.3	36

#	Article	IF	CITATIONS
19	Mutational Landscape of Virus- and UV-Associated Merkel Cell Carcinoma Cell Lines Is Comparable to Tumor Tissue. Cancers, 2021, 13, 649.	3.7	16
20	Reducing the Impact of Confounding Factors on Skin Cancer Classification via Image Segmentation: Technical Model Study. Journal of Medical Internet Research, 2021, 23, e21695.	4.3	15
21	<scp>FOXD1</scp> promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor. International Journal of Cancer, 2021, 149, 657-674.	5.1	14
22	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group. European Journal of Cancer, 2021, 149, 1-10.	2.8	10
23	Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?. International Journal of Molecular Sciences, 2021, 22, 6744.	4.1	15
24	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. European Journal of Cancer, 2021, 152, 139-154.	2.8	13
25	Tumor promoting capacity of polymorphonuclear myeloidâ€derived suppressor cells and their neutralization. International Journal of Cancer, 2021, 149, 1628-1638.	5.1	16
26	NF1-Dependent Transcriptome Regulation in the Melanocyte Lineage and in Melanoma. Journal of Clinical Medicine, 2021, 10, 3350.	2.4	2
27	TRPV1 activation and internalization is part of the LPS-induced inflammation in human iPSC-derived cardiomyocytes. Scientific Reports, 2021, 11, 14689.	3.3	13
28	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Cancers, 2021, 13, 3359.	3.7	18
29	Digital Natives' Preferences on Mobile Artificial Intelligence Apps for Skin Cancer Diagnostics: Survey Study. JMIR MHealth and UHealth, 2021, 9, e22909.	3.7	18
30	NRAS mutant melanoma: Towards better therapies. Cancer Treatment Reviews, 2021, 99, 102238.	7.7	56
31	Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. Frontiers in Oncology, 2021, 11, 741993.	2.8	9
32	Timed Ang2-Targeted Therapy Identifies the Angiopoietin–Tie Pathway as Key Regulator of Fatal Lymphogenous Metastasis. Cancer Discovery, 2021, 11, 424-445.	9.4	18
33	Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. Journal of Medical Internet Research, 2021, 23, e20708.	4.3	35
34	IER2-induced senescence drives melanoma invasion through osteopontin. Oncogene, 2021, 40, 6494-6512.	5.9	13
35	NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. European Journal of Cancer, 2021, 159, 113-124.	2.8	13
36	SOX2 in development and cancer biology. Seminars in Cancer Biology, 2020, 67, 74-82.	9.6	186

Jochen Utikal

#	Article	IF	CITATIONS
37	STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations. Cancers, 2020, 12, 119.	3.7	9
38	NF1-RAC1 axis regulates migration of the melanocytic lineage. Translational Oncology, 2020, 13, 100858.	3.7	5
39	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 2020, 585, 107-112.	27.8	526
40	Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma. Molecular Therapy - Oncolytics, 2020, 18, 83-99.	4.4	21
41	Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles. International Journal of Molecular Sciences, 2020, 21, 6319.	4.1	26
42	HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma. Cancers, 2020, 12, 3761.	3.7	7
43	Cellular Reprogramming—A Model for Melanoma Cellular Plasticity. International Journal of Molecular Sciences, 2020, 21, 8274.	4.1	14
44	Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma. Cancers, 2020, 12, 1057.	3.7	6
45	Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial. Journal of Clinical Medicine, 2020, 9, 1438.	2.4	11
46	Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. , 2020, 8, e000395.		9
47	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. Journal of Clinical Oncology, 2020, 38, 2543-2551.	1.6	40
48	Update on GNA Alterations in Cancer: Implications for Uveal Melanoma Treatment. Cancers, 2020, 12, 1524.	3.7	24
49	Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. Oncolmmunology, 2020, 9, 1727116.	4.6	52
50	T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells. British Journal of Cancer, 2020, 122, 1023-1036.	6.4	20
51	Dormant tumor cells interact with memory CD8+ T cells in RET transgenic mouse melanoma model. Cancer Letters, 2020, 474, 74-81.	7.2	12
52	Oncogenic Role of an Epigenetic Reader of m6A RNA Modification: YTHDF1 in Merkel Cell Carcinoma. Cancers, 2020, 12, 202.	3.7	38
53	Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of <i>BRAF</i> V600E mutation in plasma from melanoma patients. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1799-1807.	2.3	10
54	Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. Oncolmmunology, 2020, 9, 1744946.	4.6	37

#	Article	IF	CITATIONS
55	Tumor Cell–Derived Angiopoietin-2 Promotes Metastasis in Melanoma. Cancer Research, 2020, 80, 2586-2598.	0.9	27
56	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. International Journal of Molecular Sciences, 2020, 21, 2367.	4.1	34
57	Artificial Intelligence and Its Effect on Dermatologists' Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study. Journal of Medical Internet Research, 2020, 22, e18091.	4.3	45
58	Perspective – Escape from destruction: how cancer-derived EVs are protected from phagocytosis. Trillium Extracellular Vesicles, 2020, 2, 60-64.	0.3	2
59	A universal antiâ€cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival. International Journal of Cancer, 2019, 144, 909-921.	5.1	5
60	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. Cancer Research, 2019, 79, 4715-4728.	0.9	97
61	ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12. Cell Death and Disease, 2019, 10, 760.	6.3	18
62	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. , 2019, 7, 299.		108
63	Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCs. IScience, 2019, 12, 168-181.	4.1	24
64	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600ÂE/K–mutant advanced or metastatic melanoma. European Journal of Cancer, 2019, 109, 61-69.	2.8	63
65	Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. International Journal of Cancer, 2019, 145, 3462-3477.	5.1	46
66	Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. European Journal of Cancer, 2019, 116, 207-215.	2.8	35
67	Stem Cell-Derived Models of Neural Crest Are Essential to Understand Melanoma Progression and Therapy Resistance. Frontiers in Molecular Neuroscience, 2019, 12, 111.	2.9	23
68	A cellular model of Brugada syndrome with SCN10A variants using human-induced pluripotent stem cell-derived cardiomyocytes. Europace, 2019, 21, 1410-1421.	1.7	33
69	Characterization of six Merkel cell polyomavirusâ€positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration. International Journal of Cancer, 2019, 145, 1020-1032.	5.1	44
70	Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies. Oncotarget, 2019, 10, 1662-1663.	1.8	7
71	Serum of patients with acute myocardial infarction prevents inflammation in iPSC-cardiomyocytes. Scientific Reports, 2019, 9, 5651.	3.3	6
72	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. European Journal of Cancer, 2019, 110, 11-20.	2.8	44

#	Article	IF	CITATIONS
73	Studying Brugada Syndrome With an SCN1B Variants in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Frontiers in Cell and Developmental Biology, 2019, 7, 261.	3.7	29
74	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. Melanoma Management, 2019, 6, MMT33.	0.5	6
75	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine, 2019, 25, 1916-1927.	30.7	541
76	Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. , 2019, 7, 343.		56
77	Identification of Embryonic Neural Plate Border Stem Cells and Their Generation by Direct Reprogramming from Adult Human Blood Cells. Cell Stem Cell, 2019, 24, 166-182.e13.	11.1	39
78	Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. British Journal of Cancer, 2019, 120, 16-25.	6.4	504
79	Expression of Neural Crest Markers GLDC and ERRFI1 is Correlated with Melanoma Prognosis. Cancers, 2019, 11, 76.	3.7	11
80	Opposing roles of eosinophils in cancer. Cancer Immunology, Immunotherapy, 2019, 68, 823-833.	4.2	86
81	Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry Journal of Clinical Oncology, 2019, 37, 9505-9505.	1.6	12
82	Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. Clinical Chemistry, 2018, 64, 830-842.	3.2	50
83	Single cell polarity in liquid phase facilitates tumour metastasis. Nature Communications, 2018, 9, 887.	12.8	45
84	Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. OncoImmunology, 2018, 7, e1445457.	4.6	13
85	Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns—Results of a non-interventional study of the DeCOG. European Journal of Cancer, 2018, 96, 34-43.	2.8	97
86	Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non–Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 777-787.	5.6	129
87	Estradiol protection against toxic effects of catecholamine on electrical properties in human-induced pluripotent stem cell derived cardiomyocytes. International Journal of Cardiology, 2018, 254, 195-202.	1.7	55
88	Modeling Short QT Syndrome Using Humanâ€Induced Pluripotent Stem Cell–Derived Cardiomyocytes. Journal of the American Heart Association, 2018, 7, .	3.7	88
89	Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy. JAAD Case Reports, 2018, 4, 129-131.	0.8	0
90	Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy. Europace, 2018, 20, f46-f56.	1.7	50

#	Article	IF	CITATIONS
91	Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular Dystrophy. Circulation Genomic and Precision Medicine, 2018, 11, e001893.	3.6	40
92	CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. Cancer Research, 2018, 78, 157-167.	0.9	127
93	PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. European Journal of Cancer, 2018, 88, 67-76.	2.8	15
94	Tackling malignant melanoma epigenetically: histone lysine methylation. Clinical Epigenetics, 2018, 10, 145.	4.1	26
95	Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts. Cancers, 2018, 10, 451.	3.7	12
96	Targeting SOX2 in anticancer therapy. Expert Opinion on Therapeutic Targets, 2018, 22, 983-991.	3.4	60
97	Ion Channel Expression and Characterization in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Stem Cells International, 2018, 2018, 1-14.	2.5	60
98	Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Frontiers in Immunology, 2018, 9, 398.	4.8	354
99	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Frontiers in Immunology, 2018, 9, 1310.	4.8	404
100	RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. Oncogene, 2018, 37, 6136-6151.	5.9	91
101	Willingness to pay for a cure of low-risk melanoma patients in Germany. PLoS ONE, 2018, 13, e0197780.	2.5	9
102	Loss of neural crestâ€associated gene <i>FOXD1</i> impairs melanoma invasion and migration <i>via RAC1B</i> downregulation. International Journal of Cancer, 2018, 143, 2962-2972.	5.1	25
103	SOX2â€mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. International Journal of Cancer, 2018, 143, 3131-3142.	5.1	66
104	T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin. Cancer Immunology, Immunotherapy, 2018, 67, 1147-1157.	4.2	15
105	Abstract A180: The histone methyltransferase SETDB1 contributes to melanoma tumorigenesis. , 2018, , .		1
106	<i>MYC</i> gene amplification is a rare event in atypical fibroxanthoma and pleomorphic dermal sarcoma. Oncotarget, 2018, 9, 21182-21189.	1.8	7
107	The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. Oncotarget, 2018, 9, 26217-26225.	1.8	6
108	The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study. Oncotarget, 2018, 9, 34336-34346.	1.8	31

#	Article	IF	CITATIONS
109	Teledermatology: Comparison of Store-and-Forward Versus Live Interactive Video Conferencing. Journal of Medical Internet Research, 2018, 20, e11871.	4.3	44
110	Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. Journal of Medical Internet Research, 2018, 20, e11936.	4.3	277
111	Topography of cancer-associated immune cells in human solid tumors. ELife, 2018, 7, .	6.0	206
112	Malignes Melanom beim alten und geriatrischen Patienten. , 2018, , 527-534.		0
113	Centrifugal Surgery. Deutsches Ärzteblatt International, 2018, 115, 598.	0.9	0
114	MicroRNAs as novel targets and tools in cancer therapy. Cancer Letters, 2017, 387, 84-94.	7.2	100
115	Endothelial Notch1 Activity Facilitates Metastasis. Cancer Cell, 2017, 31, 355-367.	16.8	237
116	CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. Cancer Immunology, Immunotherapy, 2017, 66, 1015-1023.	4.2	68
117	Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. Stem Cell Reports, 2017, 8, 1379-1391.	4.8	33
118	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of Oncology, 2017, 28, 1631-1639.	1.2	549
119	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with <u>Ta</u> dalafil in patients with metastatic Melanoma (TaMe). Oncolmmunology, 2017, 6, e1326440.	4.6	74
120	Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. European Journal of Cancer, 2017, 82, 56-65.	2.8	162
121	Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. European Journal of Cancer, 2017, 81, 36-44.	2.8	76
122	Acquired IFNÎ ³ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nature Communications, 2017, 8, 15440.	12.8	195
123	Sentinel node metastasis mitotic rate (SN ―MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel nodeâ€positive melanomas. International Journal of Cancer, 2017, 140, 1907-1917.	5.1	9
124	An RNAi Screen Reveals an Essential Role for HIPK4 in Human Skin Epithelial Differentiation from iPSCs. Stem Cell Reports, 2017, 9, 1234-1245.	4.8	8
125	Lipopolysaccharides induced inflammatory responses and electrophysiological dysfunctions in human-induced pluripotent stem cell derived cardiomyocytes. Scientific Reports, 2017, 7, 2935.	3.3	111
126	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017, 547, 222-226.	27.8	1,806

#	Article	IF	CITATIONS
127	Myeloid-derived suppressor cells and tumor escape from immune surveillance. Seminars in Immunopathology, 2017, 39, 295-305.	6.1	63
128	Dâ€dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress. International Journal of Cancer, 2017, 140, 914-921.	5.1	24
129	Subtype-specific differentiation of cardiac pacemaker cell clusters from human induced pluripotent stem cells. Stem Cell Research and Therapy, 2017, 8, 229.	5.5	46
130	Targeted next generation sequencing of mucosal melanomas identifies frequent <i>NF1</i> and <i>RAS</i> mutations. Oncotarget, 2017, 8, 40683-40692.	1.8	69
131	Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. Oncotarget, 2017, 8, 76029-76043.	1.8	7
132	The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation. Oncotarget, 2017, 8, 103682-103692.	1.8	30
133	New role of ID3 in melanoma adaptive drug-resistance. Oncotarget, 2017, 8, 110166-110175.	1.8	20
134	Malignes Melanom beim alten und geriatrischen Patienten. , 2017, , 1-8.		0
135	Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. PLoS ONE, 2016, 11, e0166143.	2.5	28
136	The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. Vaccines, 2016, 4, 36.	4.4	296
137	Eignung und Probleme von Serum S100B als Biomarker zur Verlaufskontrolle bei Hochrisikoâ€Melanompatienten. JDDG - Journal of the German Society of Dermatology, 2016, 14, 158-165.	0.8	0
138	Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells. Stem Cells, 2016, 34, 832-846.	3.2	27
139	Zweites Netzwerktreffen der zertifizierten Hauttumorzentren. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1051-1052.	0.8	0
140	Loss of tumorigenic potential upon transdifferentiation from keratinocytic into melanocytic lineage. Scientific Reports, 2016, 6, 28891.	3.3	7
141	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. Journal of Immunotherapy, 2016, 39, 343-354.	2.4	21
142	Multiple roles of NF1 in the melanocyte lineage. Pigment Cell and Melanoma Research, 2016, 29, 417-425.	3.3	16
143	Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open, 2016, 1, e000068.	4.5	54
144	Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX) Tj	ETQq0 0 (1.0) rgBT /Overl 12

Medicine (United States), 2016, 95, e5375.

#	Article	IF	CITATIONS
145	SOX5 is involved in balanced MITF regulation in human melanoma cells. BMC Medical Genomics, 2016, 9, 10.	1.5	34
146	mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. Oncolmmunology, 2016, 5, e1160183.	4.6	4
147	MAP kinase pathway gene copy alterations in <i>NRAS/BRAF</i> wild-type advanced melanoma. International Journal of Cancer, 2016, 138, 2257-2262.	5.1	12
148	Predictive immune markers in advanced melanoma patients treated with ipilimumab. OncoImmunology, 2016, 5, e1158901.	4.6	23
149	<scp>TGF</scp> â€ <i>β</i> induces <scp>SOX</scp> 2 expression in a timeâ€dependent manner in human melanoma cells. Pigment Cell and Melanoma Research, 2016, 29, 453-458.	3.3	27
150	Biomarker value and pitfalls of serum S100B in the followâ€up of highâ€risk melanoma patients. JDDG - Journal of the German Society of Dermatology, 2016, 14, 158-164.	0.8	26
151	Differential Regulation of SOX9 Protein During Chondrogenesis of Induced Pluripotent Stem Cells Versus Mesenchymal Stromal Cells: A Shortcoming for Cartilage Formation. Stem Cells and Development, 2016, 25, 598-609.	2.1	44
152	Elevated chronic inflammatory factors and myeloidâ€derived suppressor cells indicate poor prognosis in advanced melanoma patients. International Journal of Cancer, 2015, 136, 2352-2360.	5.1	142
153	von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood, 2015, 125, 3153-3163.	1.4	110
154	The oak processionary moth: a new health hazard?. British Journal of General Practice, 2015, 65, 435-436.	1.4	15
155	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. Journal of Translational Medicine, 2015, 13, 351.	4.4	56
156	Acid citrate dextrose extracorporeal photopheresis is an alternative treatment option for patients with heparin allergy. International Journal of Dermatology, 2015, 54, e266-7.	1.0	1
157	Diminished levels of the soluble form of <scp>RAGE</scp> are related to poor survival in malignant melanoma. International Journal of Cancer, 2015, 137, 2607-2617.	5.1	28
158	Multiple White Cysts on Face and Trunk of a Melanoma Patient Treated with Vemurafenib. Acta Dermato-Venereologica, 2015, 95, 96-97.	1.3	4
159	Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-NaÃ ⁻ ve Patients with Metastatic Uveal Melanoma. PLoS ONE, 2015, 10, e0118564.	2.5	197
160	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet, The, 2015, 386, 444-451.	13.7	1,175
161	Ethyl 2-((4-Chlorophenyl)amino)thiazole-4-carboxylate and Derivatives Are Potent Inducers of Oct3/4. Journal of Medicinal Chemistry, 2015, 58, 5742-5750.	6.4	19
162	Function and significance of MicroRNAs in benign and malignant human stem cells. Seminars in Cancer Biology, 2015, 35, 200-211.	9.6	19

#	Article	IF	CITATIONS
163	Identification of 2-[4-[(4-Methoxyphenyl)methoxy]-phenyl]acetonitrile and Derivatives as Potent Oct3/4 Inducers. Journal of Medicinal Chemistry, 2015, 58, 4976-4983.	6.4	15
164	NF1 loss induces senescence during human melanocyte differentiation in an <scp>iPSC</scp> â€based model. Pigment Cell and Melanoma Research, 2015, 28, 407-416.	3.3	52
165	Impact of preconditioning with retinoic acid during early development on morphological and functional characteristics of human induced pluripotent stem cell-derived neurons. Stem Cell Research, 2015, 15, 30-41.	0.7	14
166	Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. Clinical and Experimental Immunology, 2015, 180, 467-474.	2.6	36
167	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. Clinical Cancer Research, 2015, 21, 5453-5459.	7.0	304
168	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 2015, 350, 207-211.	12.6	2,275
169	New therapeutic options for advanced non-resectable malignant melanoma. Advances in Medical Sciences, 2015, 60, 83-88.	2.1	40
170	PIEZO2 is required for mechanotransduction in human stem cell–derived touch receptors. Nature Neuroscience, 2015, 18, 10-16.	14.8	102
171	Ex-vivo sensitivity-directed combination chemotherapy compared to DTIC monochemotherapy in chemo-naive advanced metastastic melanoma (ChemoSensMM): A multicenter randomized phase-3 DeCOG trial Journal of Clinical Oncology, 2015, 33, e20080-e20080.	1.6	Ο
172	Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 2014, 25, 747-753.	1.2	47
173	Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up. Clinical Cancer Research, 2014, 20, 499-510.	7.0	128
174	From skin to other cell types of the body. JDDG - Journal of the German Society of Dermatology, 2014, 12, 789-792.	0.8	4
175	Von Hautzellen zu anderen Körperzellen. JDDG - Journal of the German Society of Dermatology, 2014, 12, 789-793.	0.8	1
176	Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia. Medicine (United States), 2014, 93, e161.	1.0	10
177	Efficacy of Vemurafenib in a Trametinib-Resistant Stage IV Melanoma Patient—Letter. Clinical Cancer Research, 2014, 20, 2498-2499.	7.0	4
178	SOX2 and cancer: current research and its implications in the clinic. Clinical and Translational Medicine, 2014, 3, 19.	4.0	213
179	Extracellular adenosine metabolism in immune cells in melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 1073-1080.	4.2	53
180	Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. Seminars in Cancer Biology, 2014, 28, 51-57.	9.6	63

Jochen Utikal

#	Article	IF	CITATIONS
181	Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. British Journal of Dermatology, 2014, 171, 431-433.	1.5	41
182	Myeloidâ€derived suppressor cells in malignant melanoma. JDDG - Journal of the German Society of Dermatology, 2014, 12, 1021-1027.	0.8	44
183	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New England Journal of Medicine, 2014, 371, 1877-1888.	27.0	1,572
184	De- and re-differentiation of the melanocytic lineage. European Journal of Cell Biology, 2014, 93, 30-35.	3.6	18
185	Myeloide Suppressorzellen (MDSC) beim malignen Melanom. JDDG - Journal of the German Society of Dermatology, 2014, 12, 1021-1027.	0.8	14
186	Desmoglein 2 Depletion Leads to Increased Migration and Upregulation of the Chemoattractant Secretoneurin in Melanoma Cells. PLoS ONE, 2014, 9, e89491.	2.5	25
187	Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 11-18.	2.4	78
188	Dose-dependent roles for canonical Wnt signalling in <i>de novo</i> crypt formation and cell cycle properties of the colonic epithelium. Development (Cambridge), 2013, 140, 66-75.	2.5	65
189	Mechanisms of p53 Restriction in Merkel Cell Carcinoma Cells Are Independent of the Merkel Cell Polyoma Virus T Antigens. Journal of Investigative Dermatology, 2013, 133, 2453-2460.	0.7	63
190	Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium. Journal of Cell Science, 2013, 126, e1-e1.	2.0	3
191	Mediators of induced pluripotency and their role in cancer cells – current scientific knowledge and future perspectives. Biotechnology Journal, 2012, 7, 810-821.	3.5	47
192	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 107-114.	27.0	1,976
193	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM) Journal of Clinical Oncology, 2012 30 LBA8509-I BA8509	1.6	14
194	Diagnostic and Prognostic Biomarkers in Melanoma: Current State of Play. , 2012, , 9-18.		2
195	Dexamethasone cyclophosphamide pulse therapy is highly efficient in autoimmune blistering and connective tissue disorders. European Journal of Dermatology, 2011, 21, 129-130.	0.6	1
196	Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. British Journal of Dermatology, 2011, 164, no-no.	1.5	72
197	From skin to the treatment of diseases - the possibilities of iPS cell research in dermatology. Experimental Dermatology, 2011, 20, 523-528.	2.9	27
198	Comparison of the diagnostic accuracy of whole-body MRI and whole-body CT in stage III/IV malignant melanoma. JDDG - Journal of the German Society of Dermatology, 2011, 9, 212-221.	0.8	15

#	Article	IF	CITATIONS
199	Acute Disseminated Erythematous Papulovesicular Skin Lesions in a 7-year-old Child: A Quiz. Acta Dermato-Venereologica, 2011, 91, 491-494.	1.3	4
200	Treatment of Gunpowder Tattoos with a High-Speed Diamond Drill. Dermatologic Surgery, 2010, 36, 939-941.	0.8	3
201	Combination therapy with extracorporeal photopheresis, interferonâ€Î±, PUVA and topical corticosteroids in the management of Sézary syndrome. JDDG - Journal of the German Society of Dermatology, 2010, 8, 428-438.	0.8	15
202	Die Kombinationstherapie mit extrakorporaler Photopherese, Interferon-α, PUVA und lokalen Glukokortikoiden in der Behandlung des Sézary-Syndroms. JDDG - Journal of the German Society of Dermatology, 2010, 8, 428-438.	0.8	17
203	Systemic Therapy of Non-Resectable Metastatic Melanoma. Cancers, 2010, 2, 955-969.	3.7	6
204	Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. Journal of Cell Science, 2009, 122, 3502-3510.	2.0	309
205	Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature, 2009, 460, 1145-1148.	27.8	794
206	Tumor Biomarkers in Melanoma. Cancer Control, 2009, 16, 219-224.	1.8	37
207	Reprogramming of Neural Progenitor Cells into Induced Pluripotent Stem Cells in the Absence of Exogenous Sox2 Expression. Stem Cells, 2008, 26, 2467-2474.	3.2	296
208	Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia, 2008, 22, 393-399.	7.2	94
209	Induced Pluripotent Stem Cells Generated Without Viral Integration. Science, 2008, 322, 945-949.	12.6	1,504
210	A High-Efficiency System for the Generation and Study of Human Induced Pluripotent Stem Cells. Cell Stem Cell, 2008, 3, 340-345.	11.1	508
211	Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches. Current Cancer Therapy Reviews, 2008, 4, 96-104.	0.3	1
212	Imatinib as a Treatment Option for Systemic Non-Langerhans Cell Histiocytoses. Archives of Dermatology, 2007, 143, 736-40.	1.4	71
213	Directly Reprogrammed Fibroblasts ShowÂGlobalÂEpigeneticÂRemodeling andÂWidespreadÂTissueÂContribution. Cell Stem Cell, 2007, 1, 55-70.	11.1	1,596
214	Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Archives of Dermatological Research, 2007, 298, 469-477.	1.9	47
215	Mφ1 and Mφ2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiology, 2006, 211, 473-486.	1.9	180
216	Local cutaneous argyria mimicking melanoma metastases in a patient with disseminated melanoma. Journal of the American Academy of Dermatology, 2006, 55, S92-S94.	1.2	11

#	Article	IF	CITATIONS
217	Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thrombosis and Haemostasis, 2006, 96, 611-617.	3.4	44
218	Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood, 2006, 107, 3221-3228.	1.4	183
219	Cutaneous leiomyosarcoma with myxoid alteration arising in a setting of multiple cutaneous smooth muscle neoplasms. Journal of Cutaneous Pathology, 2006, 33, 20-23.	1.3	9
220	Angioma serpiginosum in den Blaschkolinien – eine effektive Behandlung mit der IPL Technik. JDDG - Journal of the German Society of Dermatology, 2006, 4,	0.8	0
221	Additional Her 2/neu gene copies in patients with Sézary syndrome. Leukemia Research, 2006, 30, 755-760.	0.8	12
222	The expression of metastasis suppressor MIM/MTSS1 is regulated by DNA methylation. International Journal of Cancer, 2006, 119, 2287-2293.	5.1	42
223	Interleukinâ€4 and Dexamethasone Counterregulate Extracellular Matrix Remodelling and Phagocytosis in Typeâ€2 Macrophages. Scandinavian Journal of Immunology, 2005, 61, 10-17.	2.7	158
224	Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer. Cancer Letters, 2005, 219, 197-204.	7.2	16
225	Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thrombosis and Haemostasis, 2005, 94, 895-896.	3.4	20
226	Additional Cyclin D(1) gene copies associated with chromosome 11 aberrations in cutaneous malignant melanoma. International Journal of Oncology, 2005, 26, 597-605.	3.3	6
227	The Receptor for Interleukin-17E is Induced by Th2 Cytokines in Antigen-Presenting Cells. Scandinavian Journal of Immunology, 2004, 60, 233-237.	2.7	49
228	Molecular genetics of Xeroderma pigmentosum variant. Experimental Dermatology, 2003, 12, 529-536.	2.9	68
229	Predominant Telangiectatic Erythema in Linear Atrophoderma of Moulin: Novel Variant or Separate Entity?. Dermatology, 2003, 207, 310-315.	2.1	26
230	Expression of c-myc and bcl-2 in Primary and Advanced Cutaneous Melanoma. Cancer Investigation, 2002, 20, 914-921.	1.3	25
231	Chromosome 7 Aneusomy. A Marker for Metastatic Melanoma?. Neoplasia, 2001, 3, 245-254.	5.3	55
232	Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. British Journal of Cancer, 2001, 84, 72-79.	6.4	114
233	c-MYC and nodular malignant melanoma. Cancer, 2000, 89, 97-103.	4.1	25